A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sakai, Daisuke | - |
dc.contributor.author | Chung, Hyun Cheol | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Kadowaki, Shigenori | - |
dc.contributor.author | Kim, Yeul Hong | - |
dc.contributor.author | Tsuji, Akihito | - |
dc.contributor.author | Komatsu, Yoshito | - |
dc.contributor.author | Kang, Yoon-Koo | - |
dc.contributor.author | Uenaka, Kazunori | - |
dc.contributor.author | Wijayawardana, Sameera R. | - |
dc.contributor.author | Wacheck, Volker | - |
dc.contributor.author | Wang, Xuejing | - |
dc.contributor.author | Yamamura, Ayuko | - |
dc.contributor.author | Doi, Toshihiko | - |
dc.date.accessioned | 2021-09-02T22:14:39Z | - |
dc.date.available | 2021-09-02T22:14:39Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81287 | - |
dc.description.abstract | Purpose Mesenchymal-epithelial transition factor (MET) is expressed in gastric cancer and associated with poor clinical outcomes. We assessed activity, safety, and pharmacokinetics of emibetuzumab, a bivalent monoclonal anti-MET antibody that blocks ligand-dependent and ligand-independent MET signaling. Methods This non-randomized, single-arm, Phase 2 study enrolled Asian patients with MET diagnostic positive advanced gastric adenocarcinoma. Emibetuzumab (2000 mg, intravenous) was given on days 1 and 15 (28-day cycle). The primary endpoint was 8-week progression-free survival rate. Secondary objectives included safety, pharmacokinetics, overall survival, and change in tumor size. Results Tumors from 65 patients were immunohistochemically screened to enroll 15 MET diagnostic positive patients (23% positivity; 8 Japanese, 7 Korean; 10 male). Eight-week progression-free survival rate was 0.47 (70% CI, 0.33-0.59). Disease control rate was 40% (target lesion decreases, three patients; no complete/partial responses according to RECIST). Median overall survival was 17.1 weeks (95% CI, 6.3-not achievable). No serious emibetuzumab-related adverse events or new safety signals emerged. Grade >= 3 possibly drug-related adverse events were hyperkalemia, hyponatremia, and hyperuricemia (one each). Emibetuzumab's pharmacokinetics profile was similar to that observed previously. MET expression and clinical outcomes were not obviously associated. Conclusion Emibetuzumab was well tolerated with limited single-agent activity in advanced gastric adenocarcinoma. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | I DOSE-ESCALATION | - |
dc.subject | JAPANESE PATIENTS | - |
dc.subject | THERAPY | - |
dc.subject | COMBINATION | - |
dc.subject | ANTIBODY | - |
dc.subject | MONOTHERAPY | - |
dc.subject | TIVANTINIB | - |
dc.subject | LY2875358 | - |
dc.subject | PROFILES | - |
dc.subject | EGFR | - |
dc.title | A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yeul Hong | - |
dc.identifier.doi | 10.1007/s00280-017-3445-z | - |
dc.identifier.scopusid | 2-s2.0-85032217585 | - |
dc.identifier.wosid | 000415357600016 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.80, no.6, pp.1197 - 1207 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 80 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1197 | - |
dc.citation.endPage | 1207 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | I DOSE-ESCALATION | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | ANTIBODY | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | TIVANTINIB | - |
dc.subject.keywordPlus | LY2875358 | - |
dc.subject.keywordPlus | PROFILES | - |
dc.subject.keywordPlus | EGFR | - |
dc.subject.keywordAuthor | Antibodies, monoclonal, humanized | - |
dc.subject.keywordAuthor | Clinical trial | - |
dc.subject.keywordAuthor | Phase II | - |
dc.subject.keywordAuthor | LY2875358 | - |
dc.subject.keywordAuthor | MET protein, human | - |
dc.subject.keywordAuthor | Stomach neoplasms | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.